Riskpilot← Back to searchSign inGet full accessSzafran Biopsy AB
ABActiveOrg 5592193766Lejonvägen 14Research and experimental development on natural sciences and engineering · NACE 7210Est. 20190 employees
Revenue 2024
SEK 0
EBITDA margin
—
+42% vs 2023
Equity ratio
81.1%
Financial strength
Net profit 2024
SEK -201K
+46% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -100K | +42% |
| Net profit | SEK -201K | +46% |
| Total assets | SEK 852K | -4% |
| Equity | SEK 691K | -23% |
| Employees | 0 | — |
Legal name
Szafran Biopsy AB
Org number
5592193766
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20 september 2019
Share capital
SEK 69 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget ska utveckla och sälja utrustning för biopsitagning.
Address
Lejonvägen 14
Email
magnus.olsen@neodynamics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −124 | −237 | −26 | −171 | −100 |
| Depreciation & amort. | −304 | −202 | −202 | −202 | −101 |
| EBIT | −428 | −439 | −228 | −373 | −201 |
| Net financials | — | — | — | — | — |
| Profit before tax | −428 | −439 | −228 | −373 | −201 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −428 | −439 | −228 | −373 | −201 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 742 | 1 457 | 1 265 | 892 | 852 |
| Equity | 696 | 1 336 | 1 265 | 892 | 691 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 46 | 121 | 0 | 0 | 161 |
| Total debt | 46 | 121 | — | — | 161 |
EBITDA margin
-10000000.0%
This company
15.8%
Market median
-63291239% vs market
20202024
Equity ratio
81.1%
This company
38.2%
Market median
+112% vs market
20202024
Return on equity
-29.1%
This company
18.4%
Market median
-258% vs market
20202024
Net profit margin
-20100000.0%
This company
8.1%
Market median
-248148248% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KM Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2021 | |
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Szafran Biopsy AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Magnus Olsen | Chief Executive Officer | 0 companies |
| Rebecca Ann Szafran | Chairman | 0 companies |
| Sven Jörgen Vrenning | Deputy Board Member | 0 companies |